类风湿关节炎中羟氯喹、甲氨蝶呤、生物制剂与糖皮质激素相关的糖尿病发生风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入15项队列或病例对照研究、共552,019例无糖尿病的类风湿关节炎患者,评估抗风湿药物对糖尿病发生风险的影响。结果显示羟氯喹、甲氨蝶呤和TNF抑制剂与糖尿病风险降低相关,而糖皮质激素与糖尿病风险增加相关且呈剂量依赖性。
要点
- 羟氯喹、甲氨蝶呤和TNF抑制剂与类风湿关节炎患者糖尿病风险降低相关。
- 糖皮质激素与糖尿病风险增加相关,且呈剂量依赖性。
- 这些发现可能有助于类风湿关节炎的临床决策。
核心结论
- 羟氯喹、甲氨蝶呤和TNF抑制剂与类风湿关节炎患者糖尿病风险降低相关,糖皮质激素与风险增加相关。
研究设计与样本
- 系统检索PubMed、EMBASE和Cochrane Library及手工检索会议论文集,检索时间从建库至2019年10月。
- 纳入评估抗风湿药物与类风湿关节炎患者糖尿病关联的队列或病例对照研究,共15项研究、552,019例患者。
主要发现
- 羟氯喹与糖尿病风险降低相关(meta-HR 0.61,95% CI 0.56-0.66)。
- 甲氨蝶呤与糖尿病风险降低相关(meta-HR 0.81,95% CI 0.75-0.87)。
- TNF抑制剂与糖尿病风险降低相关(meta-HR 0.63,95% CI 0.55-0.71)。
- 糖皮质激素与糖尿病风险增加相关,任何剂量meta-HR 1.46(95% CI 1.39-1.53)。
- 糖皮质激素剂量依赖性:<10 mg/天泼尼松或等效剂量meta-HR 1.30(95% CI 1.13-1.51),≥10 mg/天meta-HR 2.25(95% CI 1.88-2.70)。
临床怎么用
- 在类风湿关节炎管理中,可考虑羟氯喹、甲氨蝶呤或TNF抑制剂以降低糖尿病风险。
- 使用糖皮质激素时应关注剂量依赖性糖尿病风险,尤其在高剂量时。
局限性
- 需要大型、前瞻性、设计良好的研究在糖尿病高风险类风湿关节炎患者中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of disease-modifying antirheumatic drugs on the risk of developing diabetes in rheumatoid arthritis (RA) patients without diabetes. METHODS: Electronic database searches of PubMed, EMBASE and Cochrane Library plus a hand search of conference proceedings were performed from inception to October 2019. The studies assessing the association between diabetes and antirheumatic agents in RA patients in cohort or case-control design were included. Data were pooled using fixed-effects or random-effects meta-analysis according to I2 and pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were used as summary statistic. RESULTS: A total of 15 studies involving 552,019 patients with RA (11 for hydroxychloroquine, 7 for methotrexate, 6 for tumor necrosis factor inhibitors [TNFi], and 8 for glucocorticoids) were included. In pooled analysis, a reduced risk of diabetes was reported with hydroxychloroquine (meta-HR 0.61, 95% CI 0.56-0.66), methotrexate (meta-HR 0.81, 95% CI 0.75-0.87), TNFi (meta-HR 0.63, 95% CI 0.55-0.71), while glucocorticoids was associated with an increased risk of developing diabetes in a dose-dependent manner (Any dose: meta-HR 1.46, 95% CI 1.39-1.53; <10 mg/day prednisolone or equivalent: meta-HR 1.30, 95% CI 1.13-1.51; ≥10 mg/day prednisolone or equivalent: meta-HR 2.25, 95% CI 1.88-2.70). CONCLUSIONS: Hydroxychloroquine, methotrexate and TNFi were associated with decreased risk of diabetes, and glucocorticoids with increased risk in RA patients. These important findings may aid clinical decision-making in the management of RA. Large, prospective, well-designed studies are needed in the RA patients with high-risk diabetes.
引用
- Xie W, Yang X, Ji L, et al. Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020. PMID: 32480098. doi:10.1016/j.semarthrit.2020.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。